| Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? Miniperspective DG Brown, J Bostrom Journal of medicinal chemistry 59 (10), 4443-4458, 2016 | 1289 | 2016 |
| Oxadiazoles in medicinal chemistry J Boström, A Hogner, A Llinàs, E Wellner, AT Plowright Journal of medicinal chemistry 55 (5), 1817-1830, 2012 | 597 | 2012 |
| Expanding the medicinal chemistry synthetic toolbox J Boström, DG Brown, RJ Young, GM Keserü Nature Reviews Drug Discovery 17 (10), 709-727, 2018 | 446 | 2018 |
| Assessing the performance of OMEGA with respect to retrieving bioactive conformations J Boström, JR Greenwood, J Gottfries Journal of Molecular Graphics and Modelling 21 (5), 449-462, 2003 | 358 | 2003 |
| Conformational energy penalties of protein-bound ligands J Boström, PO Norrby, T Liljefors Journal of computer-aided molecular design 12, 383-383, 1998 | 291 | 1998 |
| Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools J Boström Journal of Computer-Aided Molecular Design 15, 1137-1152, 2001 | 202 | 2001 |
| Do structurally similar ligands bind in a similar fashion? J Boström, A Hogner, S Schmitt Journal of medicinal chemistry 49 (23), 6716-6725, 2006 | 200 | 2006 |
| Where do recent small molecule clinical development candidates come from? DG Brown, J Boström Journal of medicinal chemistry 61 (21), 9442-9468, 2018 | 152 | 2018 |
| Deep Reinforcement Learning for Multiparameter Optimization in de novo Drug Design N Ståhl, G Falkman, A Karlsson, G Mathiason, J Bostrom Journal of chemical information and modeling 59 (7), 3166-3176, 2019 | 141 | 2019 |
| Molecular rift: virtual reality for drug designers M Norrby, C Grebner, J Eriksson, J Bostrom Journal of chemical information and modeling 55 (11), 2475-2484, 2015 | 124 | 2015 |
| Computational chemistry-driven decision making in lead generation V Schnecke, J Boström Drug discovery today 11 (1-2), 43-50, 2006 | 96 | 2006 |
| Scaffold hopping, synthesis and structure–activity relationships of 5, 6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists J Boström, K Berggren, T Elebring, PJ Greasley, M Wilstermann Bioorganic & medicinal chemistry 15 (12), 4077-4084, 2007 | 70 | 2007 |
| Benzothiazepine derivatives I Starke, MUJ Dahlstrom, D Blomberg, S Alenfalk, P Nordberg, ... US Patent 7,192,946, 2007 | 68 | 2007 |
| Using matched molecular series as a predictive tool to optimize biological activity NM O’Boyle, J Boström, RA Sayle, A Gill Journal of Medicinal Chemistry 57 (6), 2704-2713, 2014 | 61 | 2014 |
| Understanding Our Love Affair with p-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection DG Brown, MM Gagnon, J Bostrom Journal of Medicinal Chemistry 58 (5), 2390-2405, 2015 | 60 | 2015 |
| Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them I Starke, MUJ Dahlstrom, MP Nordberg, S Alenfalk, AC Wallberg, ... US Patent 7,238,684, 2007 | 60 | 2007 |
| Benzothiazepine derivatives I Starke, S Alenfalk, MP Nordberg, MUJ Dahlstrom, SJ Bostrom, ... US Patent 8,067,584, 2011 | 57 | 2011 |
| A 3D QSAR study on a set of dopamine D4 receptor antagonists J Boström, M Böhm, K Gundertofte, G Klebe Journal of chemical information and computer sciences 43 (3), 1020-1027, 2003 | 54 | 2003 |
| Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid J Boström, JA Grant, O Fjellström, A Thelin, D Gustafsson Journal of Medicinal Chemistry 56 (8), 3273-3280, 2013 | 48 | 2013 |
| Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor P Bach, J Bostr, K Brickmann, JJJ Van Giezen, RD Groneberg, ... European journal of medicinal chemistry 65, 360-375, 2013 | 43 | 2013 |
György M. KeserűHungarian Academy of SciencesVerified email at ttk.mta.hu
